Hims & Hers Pivots to Branded Drugs in High-Stakes Strategy Shift

Hims & Hers settles lawsuit, pivots to sell Novo Nordisk's branded weight-loss drugs. The strategic shift opens a major revenue stream but brings near-term financial pressures.

The telehealth company Hims & Hers has executed a dramatic strategic reversal, transforming from a legal adversary into a distribution partner for pharmaceutical giant Novo Nordisk. The settlement of a months-long dispute will see Hims & Hers begin selling Novo's branded weight-loss drugs, Ozempic and Wegovy, through its platform by late March, with prices starting at $149 per month. While this pivot opens a significant new revenue channel, it introduces substantial execution risks and near-term financial pressures.

A Turbulent Path to Partnership

This new alliance follows a period of significant conflict. Earlier this year, shortly after the launch of a Wegovy pill on January 5, Hims & Hers attempted to market its own compounded version of the medication. This move prompted a patent infringement lawsuit from Novo Nordisk, a reprimand from the U.S. FDA, and a threat of investigation from the Department of Justice. The telehealth firm subsequently retreated from its position.

The resolution is a formal cooperation agreement. In exchange for Novo withdrawing its lawsuit, Hims & Hers gains access to the full branded product portfolio. This includes Ozempic injections in three dosages, alongside Wegovy injections and pills across a total of six strengths. The company has already opened a waiting list for these products.

Fundamental Business Model Overhaul

The strategic shift is clear and substantial. Hims & Hers is largely discontinuing the advertising and sale of its compounded GLP-1 medications. Its future focus will be on approved, branded pharmaceuticals. Access to compounded alternatives will be maintained only for a "limited group" of patients whose needs cannot be met by the branded assortment.

Management's long-term vision is ambitious: to establish the company as the "world's largest consumer health platform for affordable, approved medications." By 2030, the leadership team is targeting revenue of $6.5 billion and adjusted EBITDA of $1.3 billion.

Near-Term Financial Headwinds Emerge

The transition is already impacting financial guidance. For the fourth quarter of 2025, Hims & Hers reported revenue of $617.8 million, a 28% year-over-year increase. However, its forecast for Q1 2026—$600 to $625 million—fell short of the analyst consensus estimate of $653 million. The company attributes this primarily to a one-time, $65 million impact from changed shipping procedures within its weight management segment, which it characterizes as temporary.

For the full 2026 fiscal year, the company anticipates revenue in the range of $2.7 to $2.9 billion.

Analysts Offer Cautious Endorsement

Equity researchers have responded with a mixed, though generally constructive, outlook. Barclays analyst Glen Santangelo raised his price target from $25 to $29, reaffirming an Overweight rating. Leerink Partners increased its target from $17.50 to $25 but maintained a neutral Market Perform rating, citing the weaker-than-expected Q1 guidance.

The consensus among 17 analysts, as of March 16, 2026, is a Hold recommendation, with an average twelve-month price target of $31.29.

The central question remains whether the new branded drug revenue can fully offset the loss of income from compounded medications. Success hinges critically on the speed at which Hims & Hers can migrate its 2.5 million subscribers to the new products and the actual pace of demand growth for Wegovy and Ozempic on its platform.